NeurAegis is developing novel calpain-2 protease inhibitors as a therapeutic strategy for traumatic brain injury (TBI) and epilepsy. These inhibitors aim to mitigate neuronal damage and inflammation, offering a potential pathway to improved outcomes for patients.